Slac2-b Inhibitors
Slac2-b inhibitors pertain to a category of chemical compounds designed to specifically target and modulate the activity of the Slac2-b protein. The Slac2-b protein, also known as synaptotagmin-like protein homologue lacking C2 domains b, is a part of the broader family of synaptotagmin-like proteins (SLPs). These proteins are known for their roles in intracellular vesicular trafficking processes. By inhibiting Slac2-b, these chemical compounds can potentially affect and regulate various cellular activities connected with vesicle transport and membrane dynamics.
The molecular mechanism of action of Slac2-b inhibitors is still a topic of ongoing research. However, it's believed that these inhibitors achieve their function by binding to specific domains or regions of the Slac2-b protein, consequently altering its conformation or preventing it from interacting with other essential cellular components. This inhibition can, in turn, disrupt the normal vesicular transport processes that Slac2-b is involved in. Elucidating the exact binding sites and the consequent downstream cellular effects is essential for a deeper understanding of the biological implications of Slac2-b inhibition. As with any class of chemical compounds, variations exist within the Slac2-b inhibitors in terms of their potency, specificity, and physicochemical properties, leading to a diverse array of compounds within this category.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
3-Methyladenine is an inhibitor of autophagy, potentially inhibiting Slac2-b by disrupting autophagic processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. It may inhibit Slac2-b indirectly by disrupting the normal autophagic processes involved in membrane trafficking. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor. By inhibiting PI3K activity, it can disrupt downstream signaling events that involve Slac2-b, thus inhibiting its function. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an inhibitor of nuclear factor-kappa B (NF-κB) activation. Slac2-b may be regulated by PI3K-dependent signaling pathways, and wortmannin can block these pathways, potentially leading to Slac2-b inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 mitogen-activated protein kinase (MAPK). Slac2-b function may be regulated by p38 MAPK signaling, and SB203580 can block this pathway, potentially inhibiting Slac2-b. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an immunosuppressive drug that inhibits the mammalian target of rapamycin (mTOR) pathway. Slac2-b may be modulated by mTOR-dependent processes, and rapamycin can inhibit these processes, potentially affecting Slac2-b. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is a fungal metabolite that disrupts the structure and function of the Golgi apparatus. Slac2-b is involved in membrane trafficking, and brefeldin A can interfere with this process by affecting Golgi function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK). Slac2-b may be modulated by JNK signaling pathways, and SP600125 can block these pathways, potentially leading to Slac2-b inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK). Slac2-b may be influenced by MEK-dependent signaling pathways, and PD98059 can disrupt these pathways, potentially affecting Slac2-b. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB202190 is a selective inhibitor of p38 MAPK, similar to SB203580. It can inhibit p38 MAPK signaling, which may indirectly affect Slac2-b function. | ||||||